At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 107 enrolled
Drug / intervention
SB480848 40mg EC Tablet +3 moredrug
Likely dose
SB480848 40mg EC Tabletfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Clinical Study of SB-480848 in Dyslipidemic Patients- A Multicenter, Randomized, Double-blind, Placebo-controlled Study of SB-480848 to Evaluate the Efficacy and Safety -
In Brief
A Phase 2 clinical trial evaluating SB480848 40mg EC Tablet, SB480848 80mg EC Tablet, and 2 other interventions for Atherosclerosis. Completed, enrolled 107 participants across 7 sites.
Detailed Summary
The primary objective of this study is to examine the effects of SB-480848 on plasma lipoprotein associated phospholipase A2 (Lp-PLA2) activity in dyslipidemic patients during a 4-week treatment with SB-480848.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtherosclerosis
CountriesJapan
Collaborators--
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedAug 2008
Enrollment StartAug 2008
Primary CompletionJan 2009
TodayJul 2026
First PostedAug 13, 2008
Enrollment StartAug 26, 2008
Primary CompletionJan 16, 2009
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 17.9 years ago
Interventions
SB480848 40mg EC Tabletdrug
1 tablet once a day
SB480848 80mg EC Tabletdrug
1 tablet once a day
SB480848 160mg EC Tabletdrug
1 tablet once a day
SB480848 Placebo Tabletdrug
1 tablet once a day